Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (CAAD-VT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05524077|
Recruitment Status : Recruiting
First Posted : September 1, 2022
Last Update Posted : September 1, 2022
Sudden cardiac death (SCD) due to recurrent ventricular tachycardia (VT) is an important clinical sequela in patients with structural heart disease. VT generally occurs as a result of electrical re-entry in the presence of arrhythmogenic substrate (scar). Scar tissue forms due to an ischemic cardiomyopathy (ICM) from prior coronary obstructive disease or a non-ischemic cardiomyopathy (NICM) from an inflammatory or genetic disease.
AADs can reduce VT recurrence, but have significant limitations in treatment of VT. For example, amiodarone has high rates of side effects/toxicities and a finite effective usage before recurrence. ICDs prevent cardiac arrest and sudden death from VT, but do not stop VT occurring. Recurrent VT and ICD therapies decrease QOL, increase hospital visits, mortality, morbidity and risk of death. Improvement in techniques for mapping and ablation of VT have made CA an alternative.
Currently, there is limited evidence to guide clinicians either toward AAD therapy or CA in patients with NICM. This data shows significant benefit of CA over medical therapy in terms of VT free survival, survival free of VT storm and VT burden. Observational studies suggest that CA is effective in eliminating VT in NICM patients who have failed AADs, resulting in reduction of VT burden and AAD use over long term follow up. Furthermore, there is limited data on the efficacy of CA in early ICM with VT, or advanced ICM with VT. RCT data is almost exclusively on patients with modest ICM with VT, and this is not representative of the real-world scenario of patients with structural heart disease presenting with VT.
Therefore the primary objective is to determine in all patients with structural heart disease and spontaneous or inducible VT, if catheter ablation compared to standard medical therapy with anti-arrhythmic drugs results in a reduction of a composite endpoint of recurrent VT, VT storm and death at a median follow up of 18 months.
|Condition or disease||Intervention/treatment||Phase|
|Heart Disease Structural Disorder Ventricular Tachycardia Cardiomyopathy, Dilated Sarcoidosis Cardiomyopathy, Hypertrophic Cardiomyopathy Ischemic Cardiomyopathy, Familial Arrhythmogenic Right Ventricular Cardiomyopathy 1 Arrhythmogenic Left Ventricular Cardiomyopathy||Procedure: Ablation Drug: Anti-arrhythmic Drugs (AADs)||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||162 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
Randomisation will be performed using a secure, password-protected web portal (REDCap) and the allocation sequence will be blinded to investigators and participants until the participants have been deemed eligible and enrolled in the study. It will not be possible to maintain blinding after study enrolment because the intervention is invasive.
Outcome verification will be blinded.
|Official Title:||Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (CAAD-VT): A Randomised Trial|
|Actual Study Start Date :||July 8, 2020|
|Estimated Primary Completion Date :||June 30, 2026|
|Estimated Study Completion Date :||June 30, 2026|
Patients will be expected to have a catheter ablation procedure within 2 weeks post randomisation and no longer than 30 days post randomisation.
Medical therapy can be used as a temporising measure before catheter ablation, as is standard of care. If there is breakthrough VT during the period before the clinical procedure, standard practice will be followed in stabilising the ventricular tachycardia (VT) including intravenous short acting anti-arrhythmic drugs (AAD), admission to hospital, internal or external cardioversion. However, preference will be given to scheduling the procedure within 24-48 hours in this situation.
Catheter ablation (CA) will be performed in the standard fashion (described in international guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death from the AHA/ACC/HRS and the expert consensus statement on Catheter Ablation of Ventricular Arrhythmias from HRS/EHRA/APHRS/LAHRS). CA will be performed under conscious sedation or GA by an Electrophysiologist trained in cardiac arrhythmia ablation. CA will be guided by a combination of mapping techniques (standard practice), and described in guidelines for CA for VT. Mapping techniques will include pace, entrainment, activation, and electro-anatomic substrate mapping, where haemodynamically tolerated. Expected procedure duration is 3-6hrs.
Post-CA, AAD is stopped if patient was drug naïve pre-randomisation. The baseline type/dose of AAD pre-randomisation is continued if the patient was on an AAD pre-randomisation. Repeat ablations are permitted within 30-days post-randomisation.
Active Comparator: Anti-arrhythmic drugs (AAD)
Patients managed with medical therapy alone by their usual medical practitioners. A protocol aligned with standard clinical care/current clinical guidelines will be provided for guidance, the objective being that the control arm replicates what would constitute standard of care for patients with ventricular tachycardia managed with a non-interventional approach.
Drug: Anti-arrhythmic Drugs (AADs)
Standard care usually encompasses patients who have not previously had AADs, being commenced on sotalol 80mg twice/day. Lower doses may be initiated by treating doctor, as clinically indicated. If there is contraindication to sotalol, another beta-blocker may be initiated using standard doses. Clinicians may consider alternative AADs if there is contraindication to beta-blockers. Doses would be up titrated to the maximal tolerated amount.
For patients already on an AAD, amiodarone would usually be added, as per VANISH trial.
They will receive a loading dose 400mg twice/day for 2 weeks, followed by 400mg/day for 4 weeks and 200mg/day thereafter. Patients who have "failed" amiodarone dose <300mg/day will receive a repeat loading dose of 400mg twice/day for 2 weeks, followed by 400mg/day for 1 week, and 300mg/day thereafter.
If the treating doctor decides to do a CA for VT, the occurrence and timepoint of cross-over will be recorded. Cross-over is estimated to be <2% (VANISH trial).
- Composite of Recurrent VT or VT storm [ Time Frame: Primary outcome will be assessed at 3-, 6-, 12-, 18-, 24-, 30-, 36- months post-randomisation. VT/VT Storm events after the 30-day treatment 'blanking' period after treatment initiation will be included. ]
VT (detected by cardiac device as lasting ≥30 seconds or shorter in duration if treated by the ICD).
VT storm (three or more documented episodes of VT within 24 hours or incessant VT).
- Death [ Time Frame: Primary outcome will be assessed at 3-, 6-, 12-, 18-, 24-, 30-, 36- months post-randomisation. Death events at any time after randomisation will be included. ]Death (at any time) due to any cause.
- Recurrent sustained VT [ Time Frame: Outcome will be assessed at 3-, 6-, 12-, 18-, 24-, 30-, 36- months post-randomisation. VT events will be included after the 30-day treatment 'blanking' period after treatment initiation. ]Recurrent sustained VT detected by implanted cardioverter defibrillator (ICD) (VT identified and treated by the ICD with anti-tachycardia pacing (ATP) and/or internal ICD delivered shock or ≥30 seconds of VT if untreated by ICD)
- VT storm [ Time Frame: Outcome will be assessed at 3-, 6-, 12-, 18-, 24-, 30-, 36- months post-randomisation. VT storm events will be included after the 30-day treatment 'blanking' period after treatment initiation. ]Three or more documented episodes of VT within 24 hours or incessant VT
- VT burden [ Time Frame: 6 months after randomisation, with a 30-day treatment 'blanking' period after treatment initiation; and 6 months before randomisation ]VT burden (number of episodes of VT in the preceding 6 months compared to the 6 months after randomisation and therapy)
- Cardiovascular hospitalisation [ Time Frame: Outcome will be assessed at 3-, 6-, 12-, 18-, 24-, 30-, 36- months post-randomisation. Events will be included after the 30-day treatment 'blanking' period after treatment initiation. ]All cardiovascular hospitalisation; heart failure; hospitalisation for arrhythmia
- Mortality [ Time Frame: Outcome will be assessed at 3-, 6-, 12-, 18-, 24-, 30-, 36- months post-randomisation. Events will be included at any time after randomisation. ]All-cause mortality; cardiovascular mortality; non-cardiac death
- Effect of intervention on ventricular function [ Time Frame: Outcome will be assessed at 3-, 6-, 12-, 18-, 24-, 30-, 36- months post-randomisation. Events will be included after the 30-day treatment 'blanking' period after treatment initiation. ]Effect of intervention on ventricular function as assessed by transthoracic echocardiography from baseline to 6-, 12-, 24- and 36-months' post intervention
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05524077
|Contact: Saurabh Kumar, MBBS, PhDfirstname.lastname@example.org|
|Contact: Timothy Campbell, BScemail@example.com|
|Australia, Australian Capital Territory|
|The Canberra Hospital||Not yet recruiting|
|Garran, Australian Capital Territory, Australia, 2605|
|Contact: Rajeev Pathak, MBBS, PhD|
|Principal Investigator: Rajeev Pathak, MBBS, PhD|
|Australia, New South Wales|
|Blacktown, New South Wales, Australia, 2148|
|Contact: Pierre Qian, MBBS, PhD|
|Principal Investigator: Pierre Qian, MBBS, PhD|
|Royal Prince Alfred Hospital||Recruiting|
|Camperdown, New South Wales, Australia, 2050|
|Contact: Kim Chan|
|Principal Investigator: Kim Chan, MBBS, PhD|
|Kingswood, New South Wales, Australia, 2747|
|Contact: Ihab El-Sokkari, MBBCh|
|Principal Investigator: Ihab El-Sokkari, MBBCh|
|John Hunter Hospital||Recruiting|
|New Lambton Heights, New South Wales, Australia, 2305|
|Contact: Nicholas Jackson, MBBS|
|Principal Investigator: Nicholas Jackson, MBBS|
|Royal North Shore Hospital||Recruiting|
|Saint Leonards, New South Wales, Australia, 2065|
|Contact: Karin Chia, MBBS, PhD|
|Principal Investigator: Karin Chia, MBBS, PhD|
|Westmead, New South Wales, Australia, 2145|
|Contact: Saurabh Kumar, MBBS, PhD|
|Principal Investigator: Saurabh Kumar, MBBS, PhD|
|The Prince Charles Hospital||Recruiting|
|Chermside, Queensland, Australia, 4032|
|Contact: Haris Haqqani, MBBS, PhD|
|Principal Investigator: Haris Haqqani, MBBS, PhD|
|Gold Coast University Hospital||Recruiting|
|Southport, Queensland, Australia, 4215|
|Contact: Matthew Rowe, MBBS|
|Principal Investigator: Matthew Rowe, MBBS|
|Australia, South Australia|
|Royal Adelaide Hospital||Recruiting|
|Adelaide, South Australia, Australia, 5000|
|Contact: Kurt Roberts-Thomson, MBBS, PhD|
|Principal Investigator: Kurt Roberts-Thomson, MBBS, PhD|
|The Alfred Hospital||Recruiting|
|Melbourne, Victoria, Australia, 3004|
|Contact: Peter Kistler, MBBS, PhD|
|Principal Investigator: Peter Kistler, MBBS, PhD|
|The Royal Melbourne Hospital||Not yet recruiting|
|Parkville, Victoria, Australia, 3050|
|Contact: Geoffrey Lee, MBChB, PhD|
|Principal Investigator: Geoffrey Lee, MBChB, PhD|
|Principal Investigator:||Saurabh Kumar, MBBS, PhD||Western Sydney Local Health District|